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The effects of cyclosporin A (CyA), an 
immunosuppressive agent that is poten-
tially nephrotoxic, on the kidneys of 9 
liver transplant recipients were studied 
with serial 99mTc-DTPA and 131I-hippu-
ran scans. In addition, renal function was 
determined by measuring serum creati-
nine levels during the second postopera-
tive week in the 9 unselected CyA-treated 
patients and, retrospectively, in a control 
group of 29 liver transplant recipients 
who had not been treated with Cy A and 
who were selected because they had sur-
vived for at least 3 months postoperative-
ly. The early postoperative creatinine 
level was significantly greater in the Cy A 
group. Eight of the 9 Cy A patients 
showed imaging abnormalities in all pre-
operative and postoperative studies. Five 
of the 8 patients showed a pattern similar 
to that of acute tubular necrosis (relative-
ly preserved perfusion) in at least one 
study. Lowering the dosage of Cy A per-
mitted the continuation of therapy, and 
all 9 patients are alive after 8 to 14 
months. 
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99mTc-DTPA and 1311-Hippuran 
Findings in Liver Transplant 
Recipients Treated with 
Cyclosporin A 1 
CYCLOSPORIN A (Cy A) is a metabolite from the fungi Cylindrocarpon lucidum and Trichoderma polysporum that has been shown to have 
a strong immunosuppressive action in a wide variety of transplant 
situations with different animal models (1-9), CyA has been suc-
cessfully used in humans who have received kidney, liver, pancreas, 
and bone marrow allografts (10-14), The drug has also produced good 
results in the treatment of chronic polyarthritis and psoriasis (15, 
16), 
The enormous potential of CyA in organ transplantation is illus-
trated by the experience of CaIne et al. (17) and by our own experience 
(18), In both CaIne's institution and ours, the projected one-year 
survival rate of primary cadaveric kidneys is 80% or better, In a recent 
series of liver recipients treated with CyA, the one-year survival rate 
for patient and graft is projected at 90% (19), However, these experi-
ences with CyA have also shown that this drug must be used with 
care, The patient has to be observed for signs of hepatotoxicity and 
nephrotoxicity (l0, 11, 13, 14), 
The possibility of nephrotoxic side effects of Cy A was first reported 
in 1978 (12), but the extent of the problem could not be defined in the 
context of renal transplantation, In a recent article we showed that 
6 out of 12 liver transplant recipients experienced at least one episode 
of possible nephrotoxicity, but that the resultant functional distur-
bances were easily and quickly reversed by downward adjustments 
of CyA dose, with no resultant rejections (20). 
The present study was undertaken in an effort to clarify the effect 
of Cy A upon radio nuclide examinations of the kidneys, without the 
confusing elements added by renal transplantation (i,e" ischemic 
acute tubular necrosis and rejection), 
MATERIALS AND METHODS 
eyA Group 
Nine patients3 received an orthotopic liver transplant between 
March and September 1980, and were treated with CyA and predni-
sone, The first dose of CyA, 15-20 mg/kg/day, was given 2 to 6 hours 
before the transplantation and continued for 8 weeks; the dose was 
then gradually reduced to about 10 mg/kg/day, The dose was de-
creased earlier if life-threatening infection occurred or if clinically 
overt nephrotoxicity developed (manifested by oliguria, azotemia, 
and elevation in the serum creatinine level). A low prednisone dose 
was also given to 8 of the patients. Intravenous steroids were ad-
ministered as well as oral steroids for treatment of rejection (13, 14, 
18), 
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TABLE I: Results of 99mTC-DTPA Renal Studies in Orthotopic Liver Transplant Recipients Treated with Cyclosporin A 
Patient Preoperative 




5 Abnormal without 
dissociation 
6 Normal 




















Posto2erative Renal Studies 
Findings' 
Abnormal without dissociation 
Abnormal with dissociation 
Abnormal without dissociation 
Abnormal without dissociation 
Abnormal with dissociation 
Abnormal without dissociation 
Abnormal with dissociation 
Abnormal with dissociation 
Abnormal with dissociation 
Abnormal with dissociation 
Normal 
Abnormal with dissociation 
Abnormal with dissociation 
Abnormal with dissociation 
Clinical Data at Time of Posto2erative Study 
Serum I otal Serum 
Cyclosporin Creatinine Bilirubin 
A Dose Level Level 
(mg/kg/day) (mg/lOO ml) (mg/lOO ml) 
11.3 2.7 l.9 
10.8 1.3 6.8 
11.4 1.0 3.9 
15.7 l.2 5.8 
9.4 6.2 1.2 
10.6 2.6 5.7 
14.8 4.2 6.5 
7.1 1.2 4.1 
7.4 2.9 1.5 
10.5 2.5 4.0 
7.6 0.7 1.0 
20.0 8.6 2.2 
7.5 1.5 1.2 
7.7 1.8 1.3 
• "Dissociation" indicates 2 or more grading points between perfusion and clearance with relatively preserved perfusion in 99mTc-DTPA renal 
study. 
Control Group 
The last 29 liver transplant recipi-
ents who were treated with azathio-
prine and prednisone (with or without 
antilymphocytic globulin) and who 
survived for more than 3 months were 
studied retrospectively to determine 
their renal function as reflected in 
serum creatinine levels. They under-
went transplantation between Sep-
tember 1976 and February 1980. Dur-
ing this period the 3-month mortality 
after liver transplantation was 41 % (14). 
Renal dysfunction usually developed 
at some time in patients who eventu-
ally died. Thus, the selection of suc-
cessful cases with conventional im-
munosuppressive therapy created a 
potential major bias in a comparis?n 
with CyA, since the 3-month mortahty 
in the i2 patients treated with CyA was 
only 8.3%. 
Laboratory Values 
Serum creatinine and total biliru-
bin levels were measured serially, in-
cluding preoperatively, in both the 
Cy A and control groups. They were 
compared using the t-test. 
Imaging Protocol and Grading 
System 
Five of the 9 patients underwent a 
baseline renal imaging study prior to 
CyA treatment and liver transplanta-
tion. In all 9 patients postoperative ra-
dionuclide imaging was done from 8 to 
154 days after transplantation, usually 
at the time when functional renal ab-
normalities developed. 
The renal imaging study consisted of 
both a 99mTc-DTPA and a 131I-hippuran 
study. No computer processing was 
done. During a single viewing session 
all studies were evaluated by one of us 
(W.c.K.) without knowledge of the 
patient's renal or liver function, or of 
the time of transplantation. In the 
99rnTc-DTP A studies, the following 
parameters were evaluated: perfusion, 
clearance, and parenchymal transit 
time. In the 131I-hippuran studies, 
clearance and parenchymal transit time 
were prolonged. Each parameter was 
graded 1 to 5, with 1 representing 
normal and 5 severe abnormality. 
Studies with poor bolus injections were 
excluded. A significant dissociation 
between perfusion and clearance was 
determined to be present when the 2 
parameters were graded 2 or more 
points apart. The grading system has 
been described in detail (21). 
RESULTS 
Laboratory Values 
Preoperatively, only one patient (in 
the control group) had an abnormal 
serum creatinine level. Postoperative-
ly, none of the control patients showed 
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an increased serum creatinine level 
more than 7 days after the transplan-
tation; 3 patients had transient episodes 
of serum creatinine level elevations of 
2.1, 4.3, and 2.7 mg/ 100 ml at 2, 3, and 
3 days, respectively. For the control 
group, the maximum serum creatinine 
levels in the second postoperative 
week ranged from 0.4 to 1.3 mg/lOO ml 
(0.87 mg/100 ml ± 0.24 S.D.). In the 
CyA-treated group the serum creati-
nine levels ranged from 0.8 to 9.2 
mg/IOO ml (3.31 mg/100 ml ± 2.47 
S.D.) during the second postoperative 
week. Five of the 9 patients had ab-
normal serum creatinine levels (> 1.5 
mg/lOO ml). Renal function during the 
second postoperative week, as judged 
from the serum creatinine levels, dif-
fered significantly between the two 
groups (p < 0.01). 
The postoperative liver function, as 
measured by total serum bilirubin 
levels, did not differ between the con-
trol group and the Cy A-treated group. 
The total serum bilirubin level for the 
CyA-treated group was 3.7 mg/ 100 ml 
± 2.1 S.D., and for the azathioprine-
treated group it was 4.7 mg/IOO ml ± 
4.2 S.D. in the second postoperative 
week. 
Imaging Studies 
Of the 5 preoperative studies, 3 
were normal and 2 were abnormal 
(TABLE I). One abnormal study showed 




. o. 0" 
9-12 sec 15-18 sec 21-24 sec 1 min 10 min 
21 Days Post-Cyclosporin A 
6-9 sec 15-18 sec 21-24 sec 1 min 10 min 
Two 99mTc-DTPA studies, pretransplantation and posttransplantation, are shown. The first study is normal (Grade 1 perfusion, clearance, and 
parenchymal transit time). The second study, after 21 days of cyclosporin A immunosuppressive therapy, shows a mild-to-moderate decrease 
in perfusion (Grade 2) and a severe decrease in clearance (Grade 4). 
dissociation between perfusion and 
clearance with relatively preserved 
perfusion, and one was abnormal 
without dissociation. "Abnormal 
without dissociation" was defined as a 
parallel decrease in both parenchymal 
transit time and clearance. 
Fourteen postoperative renal studies 
were done in the 9 patients treated 
with CyA (TABLE 1). One was normal, 
4 were abnormal without dissociation, 
and 9 showed dissociation with rela-
tively preserved perfusion (Fig. 1). Two 
of the patients with abnormal postop-
erative studies had had normal imag-
ing studies prior to transplantation. 
The findings in the 131I-hippuran 
studies were qualitatively similar to the 
findings in the 99mTc-DTPA studies, 
particularly with respect to clearance. 
For this reason, and because dissocia-
tion between perfusion and clearance 
can only be demonstrated with 
99mTc-DTPA, the 131I-hippuran find-
ings are not included in TABLE 1. 
Radionuclide studies of the kidneys 
were not performed in the retrospec-
tive control patients who were treated 
with conventional immunosuppressive 
drugs. 
DISCUSSION 
The limitations of this study are ev-
ident. Preoperative renal scans were 
obtained in only 5 of the 9 patients, and 
in 2 of them they were markedly ab-
normal before CyA therapy was insti-
tuted. An additional patient who was 
not included because postoperative 
imaging studies were not obtained also 
had pre-existing excretion abnormali-
ties with good perfusion. Thus, the 
existence of pre-existing renal abnor-
malities could be as high as 50%. Fur-
thermore, all of the 9 patients had long 
and difficult operations with many 
blood transfusions (maximum 20 liters) 
and variable bouts of intraoperative 
hypotension. Finally, the results in the 
unselected Cy A group had to be com-
pared with the results in the selected 
group of patients with favorable 
courses under conventional immuno-
suppression, none of whom had un-
Liver Transplant Recipients Treated with Cyclosporin A 
dergone radionuclide renal scanning 
before or after surgery. 
Whatever primary role pre-existent 
renal disease played, it was important 
to suspect the additional role of CyA in 
nephrotoxicity and to adjust the CyA 
dose downward accordingly. It has al-
ready been suggested that dissociation 
between perfusion and excretion in 
renal transplant recipients is a charac-
teristic drug-mediated manifestation 
(13). In the liver transplant recipients 
who all had an initial period of seem-
ingly normal renal function within 
five days, there were no safe alternative 
explanations for secondary increases in 
creatinine and blood urea nitrogen 
levels. Imperfect postoperative liver 
function could have been contributory, 
but this was also true in the retrospec-
tive control patients. 
What has emerged from these stud-
ies and, far less commonly, from ob-
servations in kidney graft recipients 
(13) is an injury pattern possibly asso-
ciated with or aggravated by CyA. It 
has been impossible to differentiate 
this pattern of well-preserved perfu-
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sion with disproportionately impaired 
excretion from that of acute tubular 
necrosis (13). This is a signal for dose 
reduction, not discontinuance, of this 
valuable drug. A parallel fall in perfu-
sion and excretion was seen at some 
time in the kidneys of 4 of the liver 
recipients, and may represent a less 
specific variant of CyA nephrotoxi-
city. 
Awareness of the potential nephro-
toxicity of CyA has been the most im-
portant factor in its proper use. In a 
previous study of many of the same 
recipients (20), the rapid reversal of 
nephrotoxicity folloWing dose reduc-
tion was documented. The importance 
of patient management has been un-
derscored by the eventual results in the 
9 patients in the present study. All 
have remained on reduced doses of 
Cy A and all 9 are still alive from 8 to 14 
months later. Kidney graft recipients 
have also undergone long-term treat-
ment with CyA (17, 18), with the ap-
propriate precautions that can often be 
delineated accurately with serial ra-
dionuclide scanning. Doubtless, the 
same principles will be important in 
managing the recipients of other or-
gans such as the heart and pancreas. If 
precautions in its use are taken, it 
seems likely that Cy A will have a more 
important impact on transplantation 
than any other development in nearly 
two decades. 
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